Last quarter (Q ), Jounce Therapeutics's total revenue was $82.00M, an increase of Infinity% from the same quarter last year. In Q, Jounce Therapeutics's net income was $50.96M. See Jounce Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 82.00M	$ 82.00M	$ 26.91M	$ 62.34M	$ 147.87M	$ 65.20M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 82.00M	$ 82.00M	-	-	-	-
Operating Expense	$ 70.92M	$ -134.24M	$ 117.96M	$ 107.46M	$ 95.06M	$ 96.50M
Operating Income	$ -52.24M	$ -52.24M	$ -91.06M	$ -45.12M	$ 52.82M	$ -31.29M
Net Non Operating Interest Income Expense	-	-	-	-	-	-
Other Income Expense	$ -16.00K	$ -1.46M	$ 199.00K	$ 1.29M	$ 4.05M	$ 3.96M
Pretax Income	$ -50.78M	$ -50.78M	$ -90.86M	$ -43.83M	$ 56.87M	$ -27.33M
Tax Provision	$ 135.00K	$ 135.00K	$ 15.00K	$ 14.00K	$ 46.00K	$ 46.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -50.92M	$ -50.92M	$ -90.87M	$ -43.84M	$ 56.82M	$ -27.38M
Basic EPS	$ -0.99	$ -0.99	$ -1.82	$ -1.24	$ 1.72	$ -0.84
Diluted EPS	$ -0.99	$ -0.99	$ -1.82	$ -1.24	$ 1.66	$ -0.84
Basic Average Shares	$ 206.69M	$ 51.68M	$ 49.93M	$ 35.43M	$ 33.08M	$ 32.57M
Diluted Average Shares	$ 206.69M	$ 51.68M	$ 49.93M	$ 35.43M	$ 34.29M	$ 32.57M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 70.92M	$ -134.24M	$ 117.96M	$ 107.46M	$ 95.06M	$ 96.50M
Net Income From Continuing And Discontinued Operation	$ -50.92M	$ -50.92M	$ -90.87M	$ -43.84M	$ 56.82M	$ -27.38M
Normalized Income	$ -101.88M	-	$ -90.87M	$ -43.84M	$ 56.82M	$ -27.38M
Interest Expense	-	-	-	-	-	-
EBIT	$ -51.51M	$ -50.78M	$ -91.06M	$ -45.12M	$ 52.82M	$ -31.29M
EBITDA	$ -49.26M	$ -47.79M	$ -88.23M	$ -41.72M	$ 56.67M	$ -27.46M

Currency in USD

Jounce Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing